EA201792595A1 - Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела - Google Patents

Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела

Info

Publication number
EA201792595A1
EA201792595A1 EA201792595A EA201792595A EA201792595A1 EA 201792595 A1 EA201792595 A1 EA 201792595A1 EA 201792595 A EA201792595 A EA 201792595A EA 201792595 A EA201792595 A EA 201792595A EA 201792595 A1 EA201792595 A1 EA 201792595A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drospyrenon
means based
patient suffering
body mass
excessive body
Prior art date
Application number
EA201792595A
Other languages
English (en)
Other versions
EA036497B1 (ru
Inventor
Доминик Друэн
Сесиль Буайе-Жубер
Филипп Перрен
Original Assignee
Лабораториос Леон Фарма Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305965.4A external-priority patent/EP3108889A1/en
Priority claimed from CN201510348953.1A external-priority patent/CN106265694A/zh
Application filed by Лабораториос Леон Фарма Са filed Critical Лабораториос Леон Фарма Са
Publication of EA201792595A1 publication Critical patent/EA201792595A1/ru
Publication of EA036497B1 publication Critical patent/EA036497B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Abstract

Дроспиренон в качестве единственного контрацептивного ингредиента, содержащегося в суточной активной единице дозирования в количестве по меньшей мере 3 мг, для применения в качестве контрацептивного средства для пациентки, страдающей ожирением.
EA201792595A 2015-06-23 2016-06-23 Способ контрацепции у пациентки, страдающей ожирением EA036497B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305965.4A EP3108889A1 (en) 2015-06-23 2015-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight
CN201510348953.1A CN106265694A (zh) 2015-06-23 2015-06-23 用于过重女性患者的基于屈螺酮的避孕药
PCT/EP2016/064574 WO2016207298A1 (en) 2015-06-23 2016-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight

Publications (2)

Publication Number Publication Date
EA201792595A1 true EA201792595A1 (ru) 2018-06-29
EA036497B1 EA036497B1 (ru) 2020-11-17

Family

ID=56178376

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792595A EA036497B1 (ru) 2015-06-23 2016-06-23 Способ контрацепции у пациентки, страдающей ожирением

Country Status (22)

Country Link
EP (1) EP3313408B1 (ru)
JP (1) JP6827962B2 (ru)
KR (1) KR102217942B1 (ru)
CN (2) CN113750108A (ru)
AU (1) AU2016282863B2 (ru)
BR (1) BR112017028048A2 (ru)
CA (1) CA2989975C (ru)
DK (1) DK3313408T3 (ru)
EA (1) EA036497B1 (ru)
FI (1) FI3313408T3 (ru)
HK (1) HK1255216A1 (ru)
HR (1) HRP20240121T1 (ru)
LT (1) LT3313408T (ru)
MX (1) MX2017016801A (ru)
MY (1) MY187233A (ru)
NI (1) NI201700173A (ru)
PH (1) PH12017502379A1 (ru)
PL (1) PL3313408T3 (ru)
RS (1) RS65196B1 (ru)
SV (1) SV2017005602A (ru)
WO (1) WO2016207298A1 (ru)
ZA (1) ZA201800067B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3106148T3 (en) 2015-06-18 2018-05-07 Mithra Pharmaceuticals S A Orodispersible dosing unit containing an estetrol component
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
EA035687B1 (ru) 2015-06-18 2020-07-27 Эстетра Спрл Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
DK3310345T3 (da) 2015-06-18 2021-05-25 Estetra Sprl Orodispersibel tablet indeholdende estetrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
CN1950092A (zh) * 2004-04-30 2007-04-18 舍林股份公司 对延长的激素避孕方案中突破性出血的控制
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
DE502005004948D1 (de) 2005-07-21 2008-09-18 Bayer Schering Pharma Ag Verfahren zur Herstellung von 3-Oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie Oxidation von 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanen
WO2011113196A1 (zh) * 2010-03-16 2011-09-22 台州太法药业有限公司 屈螺酮制备方法
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CN103372015A (zh) * 2012-04-19 2013-10-30 国家人口计生委科学技术研究所 包含屈螺酮或屈螺酮和雌激素的阴道环制剂

Also Published As

Publication number Publication date
CA2989975C (en) 2021-10-12
CA2989975A1 (en) 2016-12-29
LT3313408T (lt) 2024-03-12
SV2017005602A (es) 2018-08-14
PL3313408T3 (pl) 2024-04-15
MY187233A (en) 2021-09-13
KR102217942B1 (ko) 2021-02-19
PH12017502379A1 (en) 2018-06-25
DK3313408T3 (da) 2024-01-29
EP3313408A1 (en) 2018-05-02
AU2016282863B2 (en) 2021-05-27
RS65196B1 (sr) 2024-03-29
BR112017028048A2 (pt) 2018-09-04
JP6827962B2 (ja) 2021-02-10
EP3313408B1 (en) 2023-12-06
ZA201800067B (en) 2019-07-31
MX2017016801A (es) 2018-05-11
AU2016282863A1 (en) 2018-02-08
HRP20240121T1 (hr) 2024-04-12
WO2016207298A1 (en) 2016-12-29
NI201700173A (es) 2018-04-02
EA036497B1 (ru) 2020-11-17
CN108025014A (zh) 2018-05-11
FI3313408T3 (fi) 2024-01-25
CN113750108A (zh) 2021-12-07
JP2018527305A (ja) 2018-09-20
HK1255216A1 (zh) 2019-08-09
KR20180019173A (ko) 2018-02-23
CN108025014B (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501601B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP1898849A4 (en) NEW PROGRAMS FOR CONTRAZEPTIVE DEVICES WITH CONTROLLED DRUG DELIVERY
MX2017016802A (es) Formulaciones farmaceuticas.
TN2016000229A1 (en) Gabapentinoids and sigma receptor ligands combinations.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
TW200744610A (en) New regimens for controlled drug delivery devices for contraception
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
PH12015501538A1 (en) Topical ocular analgesic agents
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
PH12018500221A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
UA100790U (ru) Способ лечения симптомной лейомиомы матки
CL2012003685A1 (es) Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.
UA93055U (ru) Фармацевтическая композиция для дентальной имплантации
CL2012001035A1 (es) Composicion farmaceutica oral que comprende al menos un progestageno y un derivado de folato, antioxidantes y un recubrimiento antihumedad; uso de la composicion en la contracepcion.